Jane Kennet
Overview
Explore the profile of Jane Kennet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, et al.
Diabetes Obes Metab
. 2024 Apr;
26(7):2634-2644.
PMID: 38562018
Aims: To establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, in early-phase studies. Materials...
2.
Golubic R, Ismail M, Josipovic M, Kennet J, Galderisi A, Evans M
Diabetes Obes Metab
. 2023 Jun;
25(10):3059-3063.
PMID: 37312648
Aim: Evidence from mouse models suggests that brain serotonergic pathways control blood glucose. We hypothesized that sumatriptan (5HT -receptor agonist) would alter glucose homeostasis in humans. Materials And Methods: We...
3.
Inaba A, Tuong Z, Zhao T, Stewart A, Mathews R, Truman L, et al.
Nat Commun
. 2023 Apr;
14(1):2071.
PMID: 37045832
Dysfunction of interleukin-10 producing regulatory B cells has been associated with the pathogenesis of autoimmune diseases, but whether regulatory B cells can be therapeutically induced in humans is currently unknown....
4.
Zhang J, Hamey F, Trzupek D, Mickunas M, Lee M, Godfrey L, et al.
Nat Commun
. 2022 Nov;
13(1):7324.
PMID: 36443294
Despite early clinical successes, the mechanisms of action of low-dose interleukin-2 (LD-IL-2) immunotherapy remain only partly understood. Here we examine the effects of interval administration of low-dose recombinant IL-2 (iLD-IL-2)...
5.
Seelig E, Howlett J, Porter L, Truman L, Heywood J, Kennet J, et al.
JCI Insight
. 2018 Oct;
3(19).
PMID: 30282826
Background: Type 1 diabetes (T1D) results from loss of immune regulation, leading to the development of autoimmunity to pancreatic β cells, involving autoreactive T effector cells (Teffs). Tregs, which prevent...
6.
Cutler A, Oliveira J, Ferreira R, Challis B, Walker N, Caddy S, et al.
Wellcome Open Res
. 2017 Aug;
2:28.
PMID: 28815218
Background: The infection of a participant with norovirus during the adaptive study of interleukin-2 dose on regulatory T cells in type 1 diabetes (DILT1D) allowed a detailed insight into the...
7.
Todd J, Evangelou M, Cutler A, Pekalski M, Walker N, Stevens H, et al.
PLoS Med
. 2016 Oct;
13(10):e1002139.
PMID: 27727279
Background: Interleukin-2 (IL-2) has an essential role in the expansion and function of CD4+ regulatory T cells (Tregs). Tregs reduce tissue damage by limiting the immune response following infection and...
8.
Truman L, Pekalski M, Kareclas P, Evangelou M, Walker N, Howlett J, et al.
BMJ Open
. 2015 Dec;
5(12):e009799.
PMID: 26646829
Introduction: Type 1 diabetes (T1D) is caused by autoimmune destruction of the insulin-producing β cells in the pancreatic islets, leading to insulinopenia and hyperglycaemia. Genetic analyses indicate that alterations of...
9.
Heywood J, Evangelou M, Goymer D, Kennet J, Anselmiova K, Guy C, et al.
Trials
. 2015 Apr;
16:86.
PMID: 25881192
Background: A barrier to the successful development of new disease treatments is the timely recruitment of participants to experimental medicine studies that are primarily designed to investigate biological mechanisms rather...
10.
Kennet J, Hardaker N, Hobbs S, Selfe J
J Athl Train
. 2007 Dec;
42(3):343-8.
PMID: 18059988
Context: Cryotherapy is the application of cold as a treatment. It is widely used and accepted as beneficial in early management of soft tissue injury. However, the most efficient cryotherapeutic...